Organization
G. Pini Hospital, Clinical Rheumatology Unit, Milan, Italy
3 abstracts
Abstract
ANALYSIS OF ABATACEPT TREATMENT RETENTION AND EFFICACY ACCORDING TO DISEASE DURATION AND TREATMENT LINE IN A REAL-WORLD SETTINGOrg: Bristol Myers Squibb, Deepscover, Biostatistics, Puteaux, France, ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands, Schulthess Klinik, Universitätsspital Basel, Rheumatology, Basel, Switzerland,
Abstract
ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS DETERMINES 2-YEAR RETENTION OF IV AND SC ABATACEPT IN PATIENTS WITH RA IN A REAL-WORLD SETTINGOrg: Bristol Myers Squibb, ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands, University of Leeds, University of Manchester and The Christie NHS Foundation Trust, Evangelical Hospital, Department of Internal Medicine, Vienna, Austria,
Abstract
ACPA POSITIVITY DETERMINES REMISSION IN PATIENTS WITH RA TREATED WITH IV AND SC ABATACEPT: A POST HOC ANALYSIS OF THE REAL-WORLD OBSERVATIONAL ACTION AND ASCORE STUDIESOrg: Schlosspark-Klinik, University Medicine Berlin, Department of Internal Medicine, Rheumatology, Berlin, Germany, Bristol Myers Squibb, Medical Immunology & Fibrosis, Munich, Germany, Bristol Myers Squibb, MESP France – Market Access, Rueil-Malmaison, France, ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands, Bristol Myers Squibb, Global Drug Development, Princeton, United States of America,